Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Gene Manipulation Has Potential to Alter Genomes, Impact Society

Simon M. Helfgott, MD  |  Issue: January 2016  |  January 19, 2016

The National Academy of Sciences has convened a panel of experts to assess current regulations and recommend what additional oversight will be needed with regard to gene manipulation.

The National Academy of Sciences has convened a panel of experts to assess current regulations and recommend what additional oversight will be needed with regard to gene manipulation.
Image Credit: Sebastian Kaulitzki/shutterstock.com

Every so often, a major scientific breakthrough profoundly alters the trajectory of scientific research. In the 1960s, microbiologists sparked the recombinant-DNA revolution with the discovery that bacteria have innate immune systems based on restriction enzymes. These enzymes bind and cut invading viral genomes at specific short sequences, and scientists rapidly repurposed them to cut and paste DNA in vitro, transforming biologic science and giving rise to the biotechnology industry.1

In the 1970s, the seminal efforts of the late Nobel laureates, César Milstein, PhD, and Georges Köhler, PhD, in the Laboratory of Molecular Biology in Cambridge, UK, demonstrated the efficacy of monoclonal antibodies as probes to investigate the pathological pathway of neurological conditions. Although limited in scope, this initial application paved the way for the adoption of monoclonal antibodies as diagnostic tools. Perhaps more importantly, other investigators recognized their potential in the therapeutic sphere. Within years of their discovery, monoclonal antibodies served as an invaluable platform in the development of biologic therapies for rheumatic diseases.2 (See Rheuminations; January 2012, “A Short History of RA Therapeutics.”)

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In the 1980s, using the polymerase chain reaction (PCR), we learned how to speedily amplify specific DNA sequences, creating a way to generate large amounts of genetic material from a single cell, a previously laborious technique.

More recently, a fascinating discovery that allows for the easy manipulation of an organism’s genome has rocked the world of biology. Unlike some of the other scientific breakthroughs described earlier, this one has the potential to alter our genomes, and so the use or misuse of this technology will have profound implications for society.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

CRISPR: From the Yogurt Cup to the Human Genome

More than 30 years ago, scientists observed a strange pattern in some bacterial genomes: One DNA sequence would be repeated over and over again, while unique sequences would be found in between the repeats. This odd configuration, coined clustered regularly interspaced short palindromic repeats (CRISPR), was subsequently found to serve as a naturally occurring, ancient defense mechanism in a wide range of bacteria. How does it work?3

CRISPR, in combination with a set of enzymes called Cas9 (CRISPR-associated proteins), uses a guide RNA molecule to home in on its target DNA, then edits it by inserting desired sequences or disrupts it altogether. To use an analogy, these lab-made CRISPR systems are the cellular version of a word processor’s find-and-replace function.

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:discoverygenegenomeimpactpublic healthscience

Related Articles

    U.S. Scientists Unveil Powerful New Tools to Fix Genetic Faults

    October 26, 2017

    CHICAGO (Reuters)—U.S. scientists on Wednesday unveiled two new molecular editing tools designed to fix mutations that cause the majority of human genetic diseases, some of which have no known treatment. One technique, by David Liu of Harvard University and the Broad Institute of MIT and Harvard, offers a highly precise way to fix single-letter mistakes…

    Technological Advances Linked to Medical Misadventures

    April 15, 2016

    For keen students of American politics, the unending intrigue of the 2016 presidential race has been riveting. With an assemblage of aspiring candidates that, at its start, included a bevy of U.S. senators and former governors, a media-savvy real estate mogul, a renowned Hopkins neurosurgeon and an ophthalmologist, political junkies among us have feasted on…

    Genome-Wide Association Studies of SLE

    February 12, 2011

    What do these studies tell us about disease mechanisms in lupus?

    How HLA-B27 Research Landmarks, Advances Relate to Ankylosing Spondylitis Pathogenesis

    How HLA-B27 Research Landmarks, Advances Relate to Ankylosing Spondylitis Pathogenesis

    July 13, 2016

    The mechanistic link between human leukocyte antigen B27 (HLA-B27) and ankylosing spondylitis (AS) is one of the great enigmas in rheumatology. The introduction of biological therapies that target tumor necrosis factor (TNF) or the interleukin (IL) 23/IL-17A axis has had a major impact on the quality of life for many patients with AS, and one…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences